Wanbury Limited, a leading player in the pharmaceutical and API sector, posted a stunning turnaround in Q3 FY26, with profits skyrocketing nearly 12-fold year-on-year.

 

The company reported ₹15.8 crore in PAT for the quarter ending December 31, 2025, compared with just ₹1.2 crore in the same period last year, reflecting a 1,194% surge. Revenue rose 22% to ₹162.4 crore, while EBITDA jumped 82% to ₹26.9 crore, driving margins sharply higher.

 

For the nine-month period, Wanbury’s revenue touched ₹485.7 crore, up 14% from the previous year, with PAT soaring 333% to ₹44.4 crore, signaling strong operational efficiency and higher capacity utilization across its API and formulations business.

 

The company attributes its exceptional performance to robust API volumes, operational efficiencies, and effective cost management, positioning it for sustained growth in the upcoming quarters.

 

Mohan Rayana, Director, Wanbury, said that the quarter “underlines the strength of the company’s core API franchise and focus on profitable growth.”

 

He noted that revenue grew strongly, driven by “strong demand and higher volumes in our API business alongside moderate but steady growth in formulations.” On profitability, he highlighted that “PAT improved significantly from strong operations and reduced finance costs,” reflecting the benefits of improved margins and cost efficiencies.

 

Looking ahead, Rayana pointed to momentum in the API portfolio, noting the completion of a commercial shipment of a high‑potency anaesthetic API to a European customer and said the company is well positioned for growth with upcoming launches in multiple API categories.